Background/AimsAs a microvascular complication, diabetic kidney disease is the leading cause of chronic kidney disease and end‐stage renal disease worldwide. While the underlying pathophysiology driving transition of diabetic kidney disease to renal failure is yet to be fully understood, recent studies suggest that cellular senescence is central in disease development and progression. Consequently, understanding the molecular mechanisms which initiate and drive senescence in response to the diabetic milieu is crucial in developing targeted therapies that halt progression of renal disease.MethodsTo understand the mechanistic pathways underpinning cellular senescence in the context of diabetic kidney disease, we reviewed the literature using PubMed for English language articles that contained key words related to senescence, inflammation, fibrosis, senescence‐associated secretory phenotype (SASP), autophagy, and diabetes.ResultsAberrant accumulation of metabolically active senescent cells is a notable event in the progression of diabetic kidney disease. Through autocrine‐ and paracrine‐mediated mechanisms, resident senescent cells potentiate inflammation and fibrosis through increased expression and secretion of pro‐inflammatory cytokines, chemoattractants, recruitment of immune cells, myofibroblast activation, and extracellular matrix remodelling. Compounds that eliminate senescent cells and/or target the SASP – including senolytic and senomorphics drugs – demonstrate promising results in reducing the senescent cell burden and associated pro‐inflammatory effect.ConclusionsHere we evidence the link between senescence and diabetic kidney disease and highlight underlying molecular mechanisms and potential therapeutic targets that could be exploited to delay disease progression and improve outcomes for individuals with the disease. Trials are now required to translate their therapeutic potential to a clinical setting.
